Rayno Biopharma Portfolio

We are still cautious on adding new biotech positions except stocks that were mentioned last month (see Alkermes ALKS, Array ARRY and Achillion ACHN). Many biotech MO stocks are well off their highs. All positions remain as HOLDS unless you want to raise a little cash.   Albany Molecular (AMRI) is up 5%, a value play (PS 1.76) as more investors have discovered the CRO sector because more biotech companies are outsourcing R&D. AMRI is up more than 100% YTD and was added to the Portfolio on 2/10/11 at $4.68.

Technicals rule at this point near the IBB top at $176.

Here is a brief summary of our picks:

Alexion (ALXN) strong hold but way off top of $119.54.

Astex (ASTX) very speculative but with strong balance sheet.The stock is up 267% over one year.

Amgen (AMGN) strong hold.

Biogen (BIIB) strong hold.

Cubist (CBST) strong hold.

Exelixis (EXEL) weak for trades only.

Gilead (GILD) hit an intermediate top Friday so take a little off, but hard to buy on weakness.Reiterated guidance.

Immunogen (IMGN) strong hold.

Optimer (OPTR) strong hold.

Pharmacyclics (PCYC) off all time high of $95.85. MO stock weak technically.

Regeneron (REGN) high flyer MO stock hit with profit taking after blow-off last week.

Seattle Genetics (SGEN) strong hold.

Viropharma (VPHM) strong hold.

We put on a paired trade Alkermes (ALKS) long with Infinity (INFI) short and closed it out but left ALKS long.

We will review our Tools And Diagnostics Portfolio tomorrow but many are up today: ABAX, HOLX,  ILMN and QDEL.





%d bloggers like this: